Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...

that occurred after the patient crossed over from the chemotherapy arm to the nivolumab-ipilimumab arm. This death was deemed unrelated to chemotherapy. Disclosures: This research was funded by ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at ...